Screener
LivaNova LIVN Neuromodulation — Foreign currency translation adjustment
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by LivaNova in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: LivaNova’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 3:26 PM EST
- Fiscal year
- FY2025
- Accession
- 0001639691-26-000010
| Line item | Cardiopulmonary | Neuromodulation | Total |
|---|---|---|---|
| As of December 31, 2023 | $384,187 | $398,754 | $782,941 |
| Foreign currency translation adjustment | (32,935) | — | (32,935) |
| As of December 31, 2024 | 351,252 | 398,754 | 750,006 |
| Foreign currency translation adjustment | 42,834 | — | 42,834 |
| As of December 31, 2025 | $394,086 | $398,754 | $792,840 |
ITEM 16. FORM 10-K SUMMARY
FAQ
- What is LivaNova's neuromodulation — foreign currency translation adjustment?
- LivaNova (LIVN) reported neuromodulation — foreign currency translation adjustment of $0 in Q4 2025.
- What does neuromodulation — foreign currency translation adjustment mean?
- Reflects the impact of exchange rate fluctuations on the financial results of the Neuromodulation segment's international operations when translated into the reporting currency. This metric helps investors isolate operational performance from volatility in global currency markets.
Ask your AI about LivaNova's neuromodulation — foreign currency translation adjustment.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude